Lv1
70 积分 2025-09-25 加入
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
6个月前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
6个月前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
6个月前
已完结
MALAT1 regulates network of microRNA-15a/16–VEGFA to promote tumorigenesis and angiogenesis in multiple myeloma
6个月前
已完结
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
7个月前
已完结
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma
8个月前
已完结
Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy
8个月前
已完结
皖公网安备34019202002308
